Efficacy and safety of pemafibrate in patients with statin-intolerant hypercholesterolemia: results from a 12-week, randomized, double blind, placebo-controlled, phase 3 trial
Event: ESC Congress 2025
Topic: Lipid-Lowering Agents
Session: Refining efficacy and safety of lipid-lowering pharmacotherapy
Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study
Event: ESC Congress 2023
Topic: Lipid-Lowering Agents
Session: Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates
